RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $260.00 (from $269.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Biogen (BIIB) PT Lowered to $190 at Wells FargoOctober 31, 2024 6:28 AM Biogen (BIIB) PT Lowered to $290 at Leerink PartnersOctober 31, 2024 6:20 AM Biogen (BIIB) PT Lowered to $180 at BarclaysOctober 31, 2024 6:01 AM Morgan Stanley Downgrades Biogen (BIIB) to EqualweightOctober 31, 2024 3:13 AM Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) ConferenceOctober 30, 2024 7:30 PM Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) ConferenceOctober 30, 2024 7:30 PM Biogen (BIIB) PT Raised to $315 at Piper SandlerOctober 30, 2024 4:54 PM Form 8-K BIOGEN INC. For: Oct 28October 30, 2024 4:46 PM Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)October 30, 2024 4:37 PM Form 10-Q BIOGEN INC. For: Sep 30October 30, 2024 4:32 PM Biogen lifts annual profit forecast as new treatments boost earningsOctober 30, 2024 8:18 AM Biogen raises annual earnings guidance, tops Q3 estimates; shares upOctober 30, 2024 7:57 AM Form 8-K BIOGEN INC. For: Oct 30October 30, 2024 6:56 AM Biogen (BIIB) Tops Q3 EPS by 31c; raises guidanceOctober 30, 2024 6:49 AM Stocks expected to have increasing option volume: BIIB FPN EAT MDLZ CMG EA FSLR SNAP CZR QRVO CAKE BAC FHNOctober 30, 2024 4:32 AM Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological DiseasesOctober 29, 2024 6:00 PM Biogen (BIIB) Appoints Daniel Quirk, MD, as Chief Medical OfficerOctober 29, 2024 8:00 AM Biogen Appoints Daniel Quirk, MD, as Chief Medical OfficerOctober 29, 2024 8:00 AM